Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
agency, AstraZeneca, BARDA, Biomedical, compete, CoVPN, disparate, faced, finite, Fred, gated, gating, healthy, Hutchinson, instability, lingering, mid, modest, nAb, network, NextGen, NIH, outlicense, partially, pending, pipeline, regional, run, slightly, sourcing, sponsored, strength, sublicensee, submission, tailored, timepoint, transient, Trust, ultimately, uncertainty, underway, unvaccinated, unwilling, volatility
Removed:
antibody, chimpanzee, commence, deal, demonstrating, earlier, effectively, elicit, encourage, evolve, exaggerated, exhibited, flexible, half, halting, healthcare, heightened, home, immunogenic, implemented, improve, inducing, invasion, KRASmut, local, messaging, mice, monitoring, occupy, postponing, prohibiting, restricting, Russian, site, studied, superiority, supported, thereunder, transitioned, Ukraine, version, virtual, wild
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view